The diagnostic value of plasma phosphorylated tau 181 in Alzheimer’s disease within the Chinese population: A systematic review and meta-analysis DOI Open Access
Keqiang Yan,

Shuxin He,

Xiaodong Jia

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 16, 2024

Abstract Among all related biomarkers, plasma phosphorylated tau (p-tau181) has demonstrated strong diagnostic performance in the very early stages of Alzheimer’s disease (AD), showing significant differences between AD patients and healthy controls. The aim our present systematic review meta-analysis was to roundly evaluate clinical value p-tau181 based on Simoa platform Chinese populations. We systematically searched five databases (Embase, PubMed, Cochrane Library, MEDLINE, Web Science) from inception May 11th, 2024, as well references retrieved relevant articles. included prospective cohort studies retrospective case-control analysis. Out 1165 identified articles, 10 met inclusion criteria for meta-analysis. Our quantitative analysis showed that levels were significantly increased with mild cognitive impairment (MCI) compared controls (standard mean difference [SMD]: 1.45 [1.25 – 1.65], p<0.00001; SMD: 0.55 [0.31 0.78], p<0.00001) lower MCI (SMD: -0.88 [-0.93 -0.82], p<0.00001). reference values 4.48 [95% confidence interval (CI): 4.01 5.00] patients, 2.86 CI: 2.45 3.34] 2.09 1.90 2.30] confirmed increases then population. also provide reliable p-tau181, which contribute diagnosis settings.

Language: Английский

Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders DOI Creative Commons
Udit Sheth, Linn Öijerstedt, Michael G. Heckman

et al.

Molecular Neurodegeneration, Journal Year: 2025, Volume and Issue: 20(1)

Published: March 12, 2025

Abstract Background Therapeutic development for frontotemporal dementia (FTD) is hindered by the lack of biomarkers that inform susceptibility/risk, prognosis, and underlying causative pathology. Blood glial fibrillary acidic protein (GFAP) has garnered attention as a FTD biomarker. However, investigations GFAP in have been hampered symptomatic histopathologic heterogeneity small cohort sizes contributing to inconsistent findings. Therefore, we evaluated plasma biomarker compared its performance neurofilament light (NfL) protein, leading Methods We availed ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study resources conduct comprehensive cross-sectional longitudinal examination prognostic, predictive NfL largest series well-characterized presymptomatic mutation carriers participants with sporadic or familial syndromes. Utilizing single molecule array technology, measured from 161 controls, 127 carriers, 702 syndrome, 67 mild behavioral and/or cognitive changes. used multivariable linear regression Cox proportional hazard models adjusted co-variates examine utility baseline concentrations their rates change. Results Compared were elevated each syndrome but GFAP, unlike NfL, poorly discriminated controls symptoms. Similarly, both higher who later phenoconverted, better distinguished non-converters phenoconverters. additionally observed associated disease severity indicators survival, far outperformed GFAP. Nevertheless, validated findings GFAP/NfL ratio may discriminate lobar degeneration tau versus TDP-43 Conclusions Our head-to-head comparison indicate consistently outmatched prognostic susceptibility/risk people at genetic risk FTD. underscore need include evaluating new if field fully ascertain clinical value.

Language: Английский

Citations

0
Cerebrospinal fluid and blood neurofilament light chain in Parkinson's disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis DOI

Wenyi Kou,

Siming Li, Rui Yan

et al.

Journal of Neurology, Journal Year: 2025, Volume and Issue: 272(4)

Published: April 1, 2025

Language: Английский

Citations

0
Plasma p‐tau217 and neurofilament/p‐tau217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration DOI Creative Commons
Alberto Benussi,

Hanna Huber,

Kübra Tan

et al.

Alzheimer s & Dementia, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Abstract INTRODUCTION Plasma‐based biomarkers have shown promise for clinical implementation, but their accuracy in differentiating Alzheimer's disease (AD) from syndromes associated with frontotemporal lobar degeneration (FTLD) has yet to be fully investigated. This study assessed the potential of plasma differential diagnosis. METHODS cohort included 374 participants (96 AD, 278 FTLD). Plasma phosphorylated tau (p‐tau) 217 , neurofilament light chain (NfL), brain‐derived tau, glial fibrillary acidic protein, and amyloid beta 1‐42 / 1‐40 ratio were measured. Receiver operating characteristic curve analyses diagnostic accuracy, a three‐range threshold approach was used stratify patients based on most accurate biomarker. RESULTS p‐tau effectively distinguished AD FTLD, NfL/p‐tau showing superior accuracy. The identified thresholds 95% 97.5% sensitivity specificity, reducing need cerebrospinal fluid testing by 75% 54%, respectively. DISCUSSION are promising non‐invasive suggesting use as alternative traditional methods. Highlights distinguishes high chain/p‐tau showed highest FTLD. A reduces invasive or positron emission tomography imaging.

Language: Английский

Citations

0
Tau biomarkers for Neurodegenerative Diseases: current state and perspectives DOI Creative Commons
Elena Vacchi, Iñigo Ruiz‐Barrio, Giorgia Melli

et al.

Parkinsonism & Related Disorders, Journal Year: 2025, Volume and Issue: unknown, P. 107772 - 107772

Published: March 1, 2025

Language: Английский

Citations

0
Multiple System Atrophy and Progressive Supranuclear Palsy in Persian Population: A Retrospective Cross-sectional Study DOI
Mehri Salari, Kamran Rezaei,

Mohammad Javad Qalamzan

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: May 9, 2025

Abstract Background Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are neurodegenerative disorders with distinct demographic clinical profiles. In Middle Eastern countries, limited data exist on their features manifestations. Objectives This study describes MSA PSP patients in a Persian cross-sectional study. Methods was retrospectively conducted using medical records of diagnosed or between January 2019 2025, based the MDS diagnostic criteria components at initial diagnosis. Results A total 106 108 were included. MSA-C (23.58%), MSA-P (60.37%), unclassified (16.03%) subgroups this project. subtypes PSP-P (72.22%), PSP-RS (26.85%), PSP-PAGF (0.92%). The group had significantly higher age participants (71.82 ± 7.46 vs 68.85 8.66). male/female fraction compared to (70.37%/29.62% 45.28%/54.71%, p-value < 0.001). Following comparison common symptoms, onset disease before 70 years when Parkinsonism is symptom more frequent MSA, whereas after (p 0.05). Urinary problems significant (70.0%) cases (52.9%, Conclusion Describing presentations population would enhance our understanding characteristics these region.

Language: Английский

Citations

0
Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review DOI Open Access
Ioannis Liampas,

Panagiota Kyriakoulopoulou,

Vasiliki Karakoida

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11838 - 11838

Published: Nov. 4, 2024

This narrative review explores the current landscape of blood biomarkers in Frontotemporal dementia (FTD). Neurofilament light chain (NfL) may be useful differentiation behavioral variant FTD from primary psychiatric disorders (PPDs) or with Lewy bodies (DLB). In prodromal and presymptomatic mutation carriers (

Language: Английский

Citations

2
The diagnostic value of plasma phosphorylated tau 181 in Alzheimer’s disease within the Chinese population: A systematic review and meta-analysis DOI Open Access
Keqiang Yan,

Shuxin He,

Xiaodong Jia

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 16, 2024

Abstract Among all related biomarkers, plasma phosphorylated tau (p-tau181) has demonstrated strong diagnostic performance in the very early stages of Alzheimer’s disease (AD), showing significant differences between AD patients and healthy controls. The aim our present systematic review meta-analysis was to roundly evaluate clinical value p-tau181 based on Simoa platform Chinese populations. We systematically searched five databases (Embase, PubMed, Cochrane Library, MEDLINE, Web Science) from inception May 11th, 2024, as well references retrieved relevant articles. included prospective cohort studies retrospective case-control analysis. Out 1165 identified articles, 10 met inclusion criteria for meta-analysis. Our quantitative analysis showed that levels were significantly increased with mild cognitive impairment (MCI) compared controls (standard mean difference [SMD]: 1.45 [1.25 – 1.65], p<0.00001; SMD: 0.55 [0.31 0.78], p<0.00001) lower MCI (SMD: -0.88 [-0.93 -0.82], p<0.00001). reference values 4.48 [95% confidence interval (CI): 4.01 5.00] patients, 2.86 CI: 2.45 3.34] 2.09 1.90 2.30] confirmed increases then population. also provide reliable p-tau181, which contribute diagnosis settings.

Language: Английский

Citations

0